Skip to content
value.today

IGC Pharma, Inc.

IGC
$29 Mmarket cap on Oct 26, 2026
Compare
World rank
#23,113
Revenue
$1 M
For year ending March-2025
Net income
$-7 M
-560.6% margin
SEC filing
Employees
—

IGC Pharma, Inc. in brief

IGC Pharma, Inc. is a listed company in the Biotechnology industry, based in Potomac, Maryland, USA. Its market value was $29 M on 26 October 2026, which makes it the 23,113th largest listed company in the world and the 4,033rd largest in the USA on this site. In the year to March 2025 it had sales of $1 M and a net loss of $7 M. Its largest product and service lines by sales in 2025 were Plant and Cannabinoid (100%), Tolling/White labeling service (91%) and Infrastructure (13%). By market, the largest shares of its 2025 sales came from USA (100%). Its shares trade under the symbol IGC (NYSE).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About IGC Pharma, Inc.

IGC is a Maryland corporation established in 2005 with a fiscal year ending on March 31, spanning a 52- or 53-week period. Please refer to Note 1, “Nature of Operations” and Item 8 of this Annual Report on Form 10-K, for further information on business segments.

Our mission is to improve the lives of individuals affected by Alzheimer’s disease by addressing both its symptoms and the disease. Our near-term focus is on advancing IGC-AD1, our lead drug candidate currently in Phase 2 clinical trials targeting agitation in Alzheimer’s patients. We are also investing in our early-stage pipeline of investigational therapies and exploring Artificial Intelligence (AI) powered models designed to identify early markers of Alzheimer’s. We believe that combining scientific innovation with operational execution, including leveraging our internal contract research organization, positions us to efficiently advance our pipeline toward commercialization, although there can be no assurance thereof. Our long-term strategy is to build a portfolio of differentiated therapies that not only address symptomatic needs but also target disease-modifying mechanisms, thereby creating sustainable value for patients, caregivers, and shareholders.

From the company's annual report filed with the US SEC: read the report

IGC Pharma, Inc. timeline

3 events, 2005–2023
  1. 2005
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2006
  4. 🔔
    Initial public offering as India Globalization Capital, Inc.
    Final prospectus filed with the SEC on 7 March 2006; shares registered for exchange trading on 8 March 2006.
  5. 2023
  6. ✎
    Renamed IGC Pharma, Inc.
    Formerly India Globalization Capital, Inc..

Events of IGC Pharma, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
24.9×
Price / book
3.9×
Free cash flow yield
-16.8%
Net margin (TTM)
-787.2%
Operating margin
-586.6%
Return on equity
-124.1%
Liabilities / assets
23.6%
Net debt
$-1M
Revenue growth
-5.2%
R&D / revenue
288.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Mar 2018: revenue $2M, net income $-2M$2MFY18Fiscal year ending Mar 2019: revenue $5M, net income $-4M$5MFY19Fiscal year ending Mar 2020: revenue $4M, net income $-7M$4MFY20Fiscal year ending Mar 2021: revenue $1M, net income $-9M$1MFY21Fiscal year ending Mar 2022: revenue $0M, net income $-15M$0MFY22Fiscal year ending Mar 2023: revenue $1M, net income $-12M$1MFY23Fiscal year ending Mar 2024: revenue $1M, net income $-13M$1MFY24Fiscal year ending Mar 2025: revenue $1M, net income $-7M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Mar 2025$1M-5.2%$-7M$-7M-560.6%
Mar 2024$1M+47.3%$-10M$-13M-970.1%
Mar 2023$1M+127.5%$-12M$-12M-1264.8%
Mar 2022$0M-55.6%$-15M$-15M-3755.0%
Mar 2021$1M-77.9%$-9M$-9M-978.9%
Mar 2020$4M-20.5%$-7M$-7M-179.9%
Mar 2019$5M+133.8%$-5M$-4M-80.1%
Mar 2018$2M—$-2M$-2M-81.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Mar 2025$-5M$0M$-5M$-0.09—
Mar 2024$-5M$0M$-5M$-0.22—
Mar 2023$-7M$0M$-7M——
Mar 2022$-7M$0M$-8M——
Mar 2021$-11M$1M$-12M$-0.21—
Mar 2020$-9M$4M$-13M$-0.19—
Mar 2019$-3M$0M$-3M$-0.13—
Mar 2018$-2M$0M$-2M$-0.06—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$1M
Net income, trailing 12 months
$-9M
RevenueNet income
Three months to Sep 2024: revenue $0M, net income $-2M$0MSep ’24Three months to Dec 2024: revenue $0M, net income $-2M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-1M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-2M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-2M$0MSep ’25Three months to Mar 2026: revenue $0M, net income $-2M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-3M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-2M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (+73.7% on a year earlier), net income $-2M. Trailing 12 months to Sep 2026.

SEC filings

Official filings of IGC Pharma, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-7 M
Net income
$-7 M

For year ending March-2025 · source: SEC filing

Balance sheet

Total assets
$10 M
Total liabilities
$2 M
Total equity
$7 M

As of December-2025

Top 29 institutional investors in IGC Pharma, Inc.#

As of Sep 30, 2026
29 institutions held 6.3 M shares (about 5.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 5.1%. Filings read through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in IGC Pharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Geode Capital Management, LLC1,041,137+161,743 (+18.39%)0.89%$0 MNov 6, 2026
2AdvisorShares Investments LLC939,481+261,001 (+38.47%)0.81%$0 MNov 9, 2026
3Vanguard Capital Management LLC870,714+55,800 (+6.85%)0.75%$0 MNov 13, 2026
4Citadel Advisors LLC735,693+298,376 (+68.23%)0.63%$0 MNov 16, 2026
5BlackRock, Inc.703,7980 (0.00%)0.60%$0 MNov 13, 2026
6Renaissance Technologies LLC653,458+366,850 (+128.00%)0.56%$0 MNov 12, 2026
7Vanguard Fiduciary Trust Co419,4130 (0.00%)0.36%$0 MNov 13, 2026
8State Street Corp274,899+74,100 (+36.90%)0.24%$0 MNov 12, 2026
9Northern Trust Corp170,2740 (0.00%)0.15%$0 MNov 16, 2026
10UBS Group AG98,716+98,715 (+9871500.00%)0.08%$0 MNov 10, 2026
11Lawood & Co75,0000 (0.00%)0.06%$0 MOct 9, 2026
12Goldman Sachs Group Inc65,5410 (0.00%)0.06%$0 MNov 16, 2026
13Dearborn Partners LLC59,401-59,401 (-50.00%)0.05%$0 MNov 13, 2026
14Fisher Asset Management, LLC43,4000 (0.00%)0.04%$0 MNov 6, 2026
15Truist Financial Corp36,667-12,000 (-24.66%)0.03%$0 MOct 30, 2026
16Morgan Stanley35,118-80 (-0.23%)0.03%$0 MNov 13, 2026
17Schneider Downs Wealth Management Advisors, LP30,000New0.03%$0 MOct 27, 2026
18Tower Research Capital LLC (TRC)16,624-10,983 (-39.78%)0.01%$0 MNov 16, 2026
19Vanguard Global Advisers, LLC14,9440 (0.00%)0.01%$0 MNov 13, 2026
20Wealthcare Advisory Partners LLC10,0000 (0.00%)0.01%$0 MOct 21, 2026
21Burnham & Co LLC6,000+1,000 (+20.00%)0.01%$0 MNov 12, 2026
22Geneos Wealth Management Inc.3,0000 (0.00%)0.00%$0 MNov 9, 2026
23Group One Trading LLC1,806-794 (-30.54%)0.00%$0 MNov 10, 2026
24SimplyRIA Advisor Network2000 (0.00%)0.00%$0 MNov 16, 2026
25Farther Finance Advisors, LLC110+9 (+8.91%)0.00%$0 MOct 8, 2026

All 29 institutional investors: 26 to 29, with who bought and sold →

Mutual funds holding IGC Pharma, Inc.#

4 funds hold shares worth $0 M (about 1.4% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding IGC Pharma, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.814,914$0 M0.70%<0.01%+13%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC630,022$0 M0.54%<0.01%+38%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC98,554$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC95,369$0 M0.08%<0.01%no changeMay 31, 2026

As of Jun 30, 2026

Insider trading at IGC Pharma, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
11
since
IGC Pharma, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Ram MukundaCEO, DirectorGift-100,000——6.78 MForm 4
filed Claudia GrimaldiPFO, DirectorGift-150,000——3.27 MForm 4
filed Ram MukundaCEO, DirectorGift-100,000——6.68 MForm 4
filed Claudia GrimaldiPFO, DirectorGrant or award+2.05 M$0.270$553 K3.42 MForm 4
filed Ram MukundaCEO, DirectorGrant or award+2.23 M$0.270$601 K6.88 MForm 4
filed Claudia GrimaldiPFO, DirectorOption exercise+100,000——1.23 MForm 4
filed Richard K. PrinsDirectorOption exercise+100,000——1.47 MForm 4
filed Ram MukundaCEO, DirectorOption exercise+333,333——4.33 MForm 4

Markets and events: IGC Pharma, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
395,551
1 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 17,539 shares at $0.25
  • : 12,369 shares at $0.25
  • : 17,539 shares at $0.24
  • : 5 shares at $0.25
  • : 6,778 shares at $0.28

IGC Pharma, Inc. scorecard#

Passes 2 of the 8 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation0 of 5
  • Growthnot known
  • Profitabilitynot known
  • Financial health2 of 3
  • Shareholder returnsnot known

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

IGC Pharma, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

IGC Pharma, Inc.: statements by fiscal year
PeriodTrendFY 2024to Mar 31, 2025FY 2023to Mar 31, 2024FY 2022to Mar 31, 2023FY 2021to Mar 31, 2022FY 2020to Mar 31, 2021FY 2019to Mar 31, 2020FY 2018to Mar 31, 2019FY 2017to Mar 31, 2018FY 2016to Mar 31, 2017FY 2015to Mar 31, 2016
Income statement
Revenue1.31.30.90.40.94.15.12.2r0.66.4
Cost of revenue0.70.60.50.20.84.05.02.1r0.45.5
Gross profit0.60.70.40.20.10.10.10.1r0.2—
Research and development3.73.83.52.30.91.01.30.1——
Selling, general and administrative4.46.88.6137.96.03.51.7r2.3r2.7
Operating income−7.4−9.8−12−15−8.7−6.9−4.6−1.8r−2.1−2.9
Interest and finance income————————0.00.0
Interest expense and finance costs0.00.00.00.00.0——0.00.20.2
Share of profit of associates———————00.30
Other non-operating income (expense)0.30.10.10.50.10.30.50.0r0.2r0.3
Income before tax−7.1−13−12−15−8.8−7.3−4.1−1.8r−1.8−2.8
Income tax0000000.00r0.00.0
Net income including minority interests−7.1−13−12−15−8.8−7.3−4.1−1.8r−1.9−2.8
Minority interests' share of net income———————0.0r0.0−0.0
Net income attributable to shareholders−7.1−13−12−15−8.8−7.3−4.1−1.8r−1.9−2.8
Earnings per share, basic-0.09-0.22——-0.21-0.19-0.13-0.06-0.07-0.17
Earnings per share, diluted-0.09-0.22——-0.21-0.19-0.13-0.06-0.07-0.17
Shares, weighted average (basic)77595350423935282616
Shares, weighted average (diluted)7759——4239r0.00.0r2616
Balance sheet
Cash and cash equivalents0.41.23.210157.3261.7r0.5r1.5r
Short-term investments000.200.10r00.1r1.90
Receivables0.00.00.10.10.20.10.10.6r0.81.0r
Inventory1.41.52.73.55.54.20.20.5r00.2r
Other current assets0.30.10.30.30.20.2r0.00.0r0.2r0.0r
Current assets2.93.76.5152418273.2r3.63.8r
Property, plant and equipment3.23.78.29.4119.85.96.2r1.07.1r
Right-of-use (leased) assets0.10.20.30.50.50.60———
Goodwill———————00.21.2r
Other intangible assets1.91.61.20.90.40.30.20.1r00.1r
Investments in associates———————0.86.0—
Long-term investments———00.00.0————
Non-current assets5.96.2111212117.77.6r7.715r
Total assets8.79.9172736293411r1119r
Accounts payable0.90.80.51.00.50.80.30.3r0.40.3r
Current liabilities2.32.31.92.42.41.90.92.3r1.33.2r
Long-term debt0.10.10.10.10.30——0.50.8r
Lease liabilities (non-current)0.00.10.20.30.40.50———
Non-current liabilities0.20.20.40.50.70.50.00.4r2.61.7r
Total liabilities2.42.62.32.93.12.40.92.8r3.94.9r
Retained earnings−121−114−101−89−74−65−58−54r−52−50r
Shareholders' equity6.37.315243327348.1r7.413r
Minority interests———————0−0.00.5r
Total equity————3327348.1r7.4r14r
Total liabilities and equity8.79.9172736293411r1119r
Shares outstanding816753514839403128r23r
Cash-flow statement
Depreciation and amortization0.60.60.70.70.50.10.10.0r0.40.7
Share-based compensation4.34.65.57.00.70.50.5r0.60.3r0.2
Cash from operating activities−4.8−5.2−7.0−7.5−11−8.7−3.3−1.9r−1.4−0.2
Capital expenditure−0.1−0.1−0.3−0.2r−1.5−4.4−0.0−0.1r−0.1−0.1
Intangible assets bought−0.4−0.4−0.3−0.5−0.1−0.1−0.0———
Acquisitions, net of cash acquired——————−0.0−0.1r0−0.0
Cash from investing activities−0.4−0.3−0.2−0.73.4−9.5−0.3−0.7r−0.2−0.2
Debt repaid−0.0−0.0−0.0−0.0——————
Shares issued4.53.00.1—14−0.1293.5r0.61.7
Cash from financing activities4.53.50.14.115−0.1283.7r0.71.0
Exchange-rate effect on cash————0.0−0.1−0.1−0.0r−0.0−0.0
Change in cash−0.8−2.0−7.3−4.17.3−18241.1r−1.00.7
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2025

What IGC Pharma, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Plant and Cannabinoid$1 M100%
  • Tolling/White labeling service$1 M91%
  • Infrastructure$0 M13%
  • Wellness and Lifestyle$0 M8.9%

Countries and regions

As of Mar 31, 2025

Where IGC Pharma, Inc. operates: 4 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.

IGC Pharma, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office$1 M100%
🇮🇳 India4 subsidiaries—
🇨🇴 Colombia1 subsidiary—
🇭🇰 Hong Kong1 subsidiary—

Executive pay at IGC Pharma, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$568 K
Mr. Ram Mukunda
Other top executives, average
$259 K
the CEO earned 2.2× this
$100 invested is now
$82000
IGC Pharma, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Ram Mukunda$568 K−$203 K$259 K$82000
2024Mr. Ram Mukunda$1.8 M$2.7 M$717 K—

As of Mar 31, 2025

Events at IGC Pharma, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 11 · New debt 4 · Unregistered share sale 5 · Bylaws or fiscal year changed 2 · Shareholder vote 3

IGC Pharma, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share sale8-K
Material agreementNew debt8-K
Material agreementNew debtUnregistered share sale8-K
Material agreementNew debtUnregistered share sale8-K
Material agreement8-K
Bylaws or fiscal year changed8-K
Bylaws or fiscal year changed8-K
Acquisition or sale completed8-K
Shareholder vote8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Material agreementNew debt8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Directors and officers8-K
Material agreement8-K
Shareholder vote8-K

As of Jul 6, 2026

Acquisitions and funding#

3 acquisitions, $2 M paid where reported

Businesses it acquired

Acquisitions by IGC Pharma, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Golden Gate Electronics Limited ("Golden Gate")2014—$1 M51%Annual report
Techni Bharathi Limited ("TBL")2013—$0 M—Annual report
H&F Ironman Limited ("HK Ironman")2012—$1 M—Annual report

How IGC Pharma, Inc. compares in Biotechnology

  • Market cap$29 M · higher than 21% of 733
  • Revenue$1 M · higher than 27% of 649
  • Net margin-787.2% · higher than 4% of 407
  • Revenue growth-5.2% · higher than 38% of 441
  • Price / sales24.9× · lower than 28% of 344
  • Price / book3.9× · lower than 38% of 537
  • FCF yield-16.8% · higher than 47% of 456

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
IGC Pharma, Inc.🇺🇸$29 M—-787.2%-5.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Oct 26, 2026
Annual results:
For year ending March-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 22, 2026

How each figure is collected: methodology. Market caps in US dollars unless you switch the currency.

Work at IGC Pharma, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show IGC Pharma, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about IGC Pharma, Inc.? Suggest a correction